Go online to PeerView.com/DFQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel antibody platforms—including agents directed against targets such as CD38 and BCMA—have proven efficacy in a range of multiple myeloma (MM) treatment settings and have clear treatment roles across the spectrum of care, from newly diagnosed MM to relapsed/refractory disease. Additionally, a new wave of immune-based treatments in the form of bispecific T-cell–engaging antibodies shows a great deal of promise and may soon add another layer of complexity to the selection and use of antibody platforms in MM. This activity features a panel of hematology-oncology experts illustrating the clinical implications of current and emerging evidence that supports an expanded role for therapeutic use/planning of antibody and immunotherapy options in MM. Upon completion of this activity, participants should be better able to: Summarize current evidence and guideline recommendations surrounding the use of novel antibody platforms in multiple myeloma (MM); Integrate established and emerging immunotherapy options, including monoclonal antibodies, antibody–drug conjugates, and bispecific antibodies, into treatment plans for patients with MM based on guideline recommendations and the latest clinical data; and Address practical aspects of immunotherapy options in MM, including unique safety considerations and effective sequential use of antibody-based therapy
View all episodes
